Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |
|---|---|---|---|---|
| Revenue | $357 | $8 | $0 | $0 |
| % Growth | 4,163.2% | – | – | – |
| Cost of Goods Sold | $116 | $2 | $0 | $0 |
| Gross Profit | $241 | $6 | $0 | $0 |
| % Margin | 67.6% | 77.4% | – | – |
| R&D Expenses | $0 | $29 | $25 | $40 |
| G&A Expenses | $2,976 | $12,628 | $6,069 | $2,053 |
| SG&A Expenses | $4,147 | $15,771 | $6,216 | $2,135 |
| Sales & Mktg Exp. | $1,171 | $3,143 | $147 | $82 |
| Other Operating Expenses | $58 | $0 | $3 | $0 |
| Operating Expenses | $4,256 | $15,837 | $6,361 | $2,305 |
| Operating Income | -$3,957 | -$17,373 | -$6,361 | -$2,305 |
| % Margin | -1,108.7% | -207,542.2% | – | – |
| Other Income/Exp. Net | $896 | -$61,820 | -$688 | -$281 |
| Pre-Tax Income | -$3,061 | -$77,651 | -$7,926 | -$2,412 |
| Tax Expense | $0 | $3,156 | -$286 | -$43 |
| Net Income | -$3,042 | -$78,013 | -$7,634 | -$2,339 |
| % Margin | -852.4% | -931,940.1% | – | – |
| EPS | -0.007 | -0.24 | -0.051 | -0.025 |
| % Growth | 97.3% | -367.8% | -108.5% | – |
| EPS Diluted | -0.007 | -0.24 | -0.051 | -0.025 |
| Weighted Avg Shares Out | 470,493 | 322,641 | 148,669 | 94,996 |
| Weighted Avg Shares Out Dil | 470,493 | 322,641 | 148,669 | 94,996 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $49 | $4,337 | $3 | $30 |
| Depreciation & Amortization | $109 | $37 | $91 | $130 |
| EBITDA | -$2,903 | -$17,336 | -$5,337 | -$2,132 |
| % Margin | -813.3% | -207,095.9% | – | – |